Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Positive results of long-term phase of AEGIS-CKD study further demonstrate the benefits of Feraccru®

29 Jan 2019

Shield Therapeutics plc, announces positive results from the open-label extension phase of the AEGIS-CKD pivotal study of Feraccru®, a novel oral ferric iron therapy that is approved and marketed in the European Union for the treatment of iron deficiency (ID) in adults and in Switzerland for the treatment of iron deficiency anaemia (IDA) in adults with inflammatory bowel disease (IBD).

For further information click here.

Back to news